{"analyses":[{"ciLowerLimit":"0.75","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.00","estimateComment":"Reference level = Conventional adjuvant TMZ","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.06","pValueComment":"Two-side significance level = 0.05","paramType":"Hazard Ratio (HR)","paramValue":"0.87","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.7","upperLimit":"6.1","value":"5.5"},{"groupId":"OG001","lowerLimit":"6.2","upperLimit":"7.7","value":"6.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"411"},{"groupId":"OG001","value":"420"}],"units":"Participants"}],"description":"Progression is defined as greater than 25% increase in tumor area (two diameters) provided that the patient has not had his/her dose of steroids decreased since the last evaluation period. Progression-free survival time is defined as time from registration to the date of first progression, death, or last known follow-up (censored). Progression-free survival rates are estimated using the Kaplan-Meier method. A concomitant decrease in steroid dose will rule out a progression designation during the first 2 months after completion of radiation therapy. Analysis occurred after 647 deaths were reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle.","id":"OG000","title":"Conventional Adjuvant TMZ"},{"description":"Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle.","id":"OG001","title":"Dose-dense Adjuvant TMZ"}],"paramType":"MEDIAN","populationDescription":"Randomized eligible patients","reportingStatus":"POSTED","timeFrame":"From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.","title":"Median Progression-free Survival (PFS) Time","type":"SECONDARY","unitOfMeasure":"months"}